Company Profile

Constellation Pharmaceuticals, Inc. discovers and develops small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders and other diseases. The Company has three clinical-stage oncology development programs: the first program is evaluating a compound, CPI-0610, other program is evaluating a compound, CPI-1205 and CPI-0209 is initiate Phase I clinical trial and targeting solid tumors. CPI-1205 is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. CPI-0610 is a potent and selective small molecule designed to promote anti-tumor activity by selectively inhibiting the function of BET proteins, which are proteins that normally enhance target gene expression. The Company is conducting the ProSTAR trial, which is an open-label Phase Ib/2 clinical trial of CPI-1205 for the treatment of mCRPC in combination with enzalutamide and abiraterone acetate.

Employees

154

Sector

Biotechnology & Medical Research

More about the company

22-12-06	MorphoSys Out Licenses Pre-Clinical Oncology Program	CI
21-07-16	MorphoSys : Royalty Pharma Takes Equity Position in MorphoSys for $100 Million	MT
21-07-15	Constellation Announces Management Changes	CI
21-07-15	Constellation Pharmaceuticals, Inc. Announces Resignation of Jigar Raythatha as Chief Executive Officer	CI
21-07-15	Constellation Pharmaceuticals, Inc. Announces Resignation of Emma Reeve as Chief Financial Officer	CI
21-07-15	DJ Industrial : Wall Street Futures Mostly Lower, Jobless Claims Drop Less Than Expected; Powell Speech Eyed	MT
21-07-15	MorphoSys : Finalizes $1.7 Billion Acquisition of Constellation Pharmaceuticals	MT
21-07-15	MorphoSys : Completes Tender Offer for Constellation Pharmaceuticals	MT
21-07-15	Constellation Pharmaceuticals, Inc.(NasdaqGM:CNST) dropped from NASDAQ Composite Index	CI
21-07-15	Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from S&P TMI Index	CI
21-07-15	Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from S&P Biotechnology Select Industry Index	CI
21-07-15	Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from S&P Global BMI Index	CI
21-07-14	MorphoSys AG completed the acquisition of Constellation Pharmaceuticals, Inc..	CI

21-06-17	Constellation Pharmaceuticals : RBC Capital Downgrades Constellation Pharmaceuticals to Sector Perform From Outperform, Price Target Cut to $34 From $50	MT
21-06-04	Constellation Pharmaceuticals : Jefferies Downgrades Constellation Pharmaceuticals to Hold From Buy, Adjusts Price Target to $34 From $53	MT
21-06-03	Constellation Pharmaceuticals : Truist Securities Downgrades Constellation Pharmaceuticals to Hold From Buy, Adjusts PT to $34 From $50	MT
21-06-03	Constellation Pharmaceuticals : BMO Capital Downgrades Constellation Pharmaceuticals to Market Perform from Outperform, Adjusts Price Target to $34 from $48	MT
21-06-03	Constellation Pharmaceuticals : JPMorgan Downgrades Constellation Pharmaceuticals to Neutral from Overweight, Adjusts Price Target to $34 from $38	MT

21-07-19	Royalty Pharma : MorphoSys Concludes a US$ 100 Million Capital Increase to Implement the Purchase of 1,337,552 shares by Royalty Pharma	AQ
21-07-16	MorphoSys AG :	AQ
21-07-15	Constellation Pharmaceuticals : Completion of Acquisition or Disposition of Assets (Form 8-K)	PU
21-07-15	CONSTELLATION PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
21-06-14	Constellation Pharmaceuticals : Provides an Update from the Ongoing MANIFEST Study of Pelabresib	AQ

21-07-29	Morphosys macht mehr Umsatz - Operativer Verlust höher
21-07-28	Morphosys verbucht in 2Q dank Finanzerträgen Gewinn
21-07-27	AKTIE IM FOKUS 2: MorphoSys setzen Talfahrt fort - Commerzbank streicht 'Buy'
21-07-26	MÄRKTE EUROPA/Etwas leichter - Bitcoin mit Rally
21-07-26	XETRA-SCHLUSS/Leichte Abgaben zu Wochenbeginn - Morphosys brechen ein

Manager	Title	Age	Since
John McKenna PSD	President	-	-
Kia Khalaghpour IRC	Investor Relations Contact	-	-
Irina Apostolou PRN	Corporate Officer/Principal	-	2016-07-31

Constellation Pharmaceuticals, Inc. Stock

Stocks

CNST

US2103731061

Biotechnology & Medical Research

Latest news : Constellation Pharmaceuticals, Inc.

Analysts' recommendations: Constellation Pharmaceuticals, Inc.

Press Releases: Constellation Pharmaceuticals, Inc.

News in other languages: Constellation Pharmaceuticals, Inc.

Quotes and Performance

Managers and Directors: Constellation Pharmaceuticals, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Director	Title	Age	Since
Kathleen Warnecke BRD	Director/Board Member	-	2021-07-14
John McKenna BRD	Director/Board Member	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/15/21	Mark Goldsmith	Issuer sale	Chief Executive Officer	157,724	0.3288%
7/15/21	Scott Braunstein	Issuer sale	Director	52,684	0.1098%
7/15/21	James E. Audia	Issuer sale	Chief Technology Officer	131,179	0.2735%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CONSTELLATION PHARMACEUTICALS, INC.	+0.06%	+0.12%	-	-	1.62B
WUXI APPTEC CO., LTD.	-0.73%	+7.82%	+73.81%	+102.34%	70.51B
ARGENX SE	+1.60%	+1.66%	+37.76%	+67.36%	54.05B
INSMED INCORPORATED	-0.22%	+33.59%	+8.43%	+489.75%	28.95B
WUXI BIOLOGICS (CAYMAN) INC.	-0.66%	+9.67%	+47.34%	+6.65%	24.05B
BIONTECH SE	-0.06%	+0.61%	-16.45%	-13.26%	23.31B
PHARMAESSENTIA CORPORATION	-1.37%	+7.87%	+251.71%	+464.53%	18.67B
GENMAB A/S	+2.21%	+7.66%	+47.18%	-20.09%	18.37B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	0.00%	+4.13%	+26.43%	+624.66%	16.1B
EXELIXIS, INC.	-1.85%	-11.15%	+32.75%	+134.11%	12.72B
Average	-0.10%	+8.58%	+56.55%	+206.23%	29.64B
Weighted average by Cap.	+0.01%	+9.58%	+54.93%	+168.53%